anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Chronic abdominal pain in children is occasionally caused by anterior cutaneous nerve entrapment syndrome (ACNES). Diagnosing and treating this typical peripheral abdominal wall neuropathy is challenging. Management usually starts with minimally invasive tender point injections. Nevertheless, these injections can be burdensome and might even be refused by children or their parents. However, a surgical neurectomy is far more invasive. Treatment with a Lidocaine 5% medicated patch is successfully used in a variety of peripheral neuropathies.
AIMS: This single center retrospective case series aimed to evaluate the effectiveness and tolerability of lidocaine patches in children with ACNES.
METHODS: Children aged under 18 diagnosed with ACNES who were treated with a 10 day lidocaine patch treatment between December 2021 and December 2022 were studied. Patient record files were used to collect treatment outcomes including pain reduction based on NRS and complications.
RESULTS: Twelve of sixteen children (mean age 13 years; F:M ratio 3:1) diagnosed with ACNES started the lidocaine patch treatment. Two patients achieved a pain free status and remained pain free during a 4 and 7 months follow-up. A third child reported a lasting pain reduction, but discontinued treatment due to a temporary local skin rash. Five additional patients reported pain reduction only during application of the patch. The remaining four children experienced no pain relief. No adverse effects were reported.
CONCLUSION: Lidocaine patches provides pain relief in a substantial portion of children with ACNES.
Participants in this arm will receive the test product, which is an alcohol alternative herbal tincture. The intervention includes taking 2 ml of the test product directly onto the tongue every evening, 1-2 hours before bedtime, for a duration of 8 weeks.
Rationale: Adult neurogenesis in the subventricular zone (SVZ) is essential for maintaining neural homeostasis, and its dysregulation contributes to anosmia and delayed tissue healing in neurological disorders, such as Parkinson's disease (PD). Despite intricate regulatory networks identified in SVZ neurogenesis, the molecular mechanisms dynamically maintaining neural stem/progenitor cells (NSPCs) in response to physiological and pathological stimuli remain incompletely elucidated. Methods: We generated an RNA binding motif protein 24 (Rbm24) knockout model to investigate its impact on adult neurogenesis in the SVZ, employing immunofluorescence, immunoblot, electrophysiology, RNA-sequencing, and in vitro experiments. Further investigations utilized a PD mouse model, along with genetic and pharmacological manipulations, to elucidate Rbm24 involvement in PD pathology. Results: Rbm24, a multifaceted post-transcriptional regulator of cellular homeostasis, exhibited broad expression in the SVZ from development to aging. Deletion of Rbm24 significantly impaired NSPC proliferation in the adult SVZ, ultimately resulting in collapsed neurogenesis in the olfactory bulb. Notably, Rbm24 played a specific role in maintaining Notch1 mRNA stability in adult NSPCs. The Rbm24/Notch1 signaling axis was significantly downregulated in the SVZ of PD mice. Remarkably, overexpression of Rbm24 rescued disruption of adult neurogenesis and olfactory dysfunction in PD mice, and these effects were hindered by DAPT, a potent inhibitor of Notch1. Conclusions: Our findings highlight the critical role of the Rbm24/Notch1 signaling axis in regulating adult SVZ neurogenesis under physiological and pathological circumstances. This provides valuable insights into the dynamic regulation of NSPC homeostasis and offers a potential targeted intervention for PD and related neurological disorders.
This is a prospective observational study including patients undergoing TAVI with either self- or balloon-expandable valves. After the procedure, patients will be on ECG monitoring during the hospitalization period (or at least 72 hours), and an ECG will be performed daily until hospital discharge in all patients. Patients with new-onset persistent LBBB at hospital discharge (new-onset LBBB of a duration of at least 48 h which persists at hospital discharge, at least 3 days and up to 15 days after the procedure) will receive an implantable loop recorder Reveal ICM LINQ®, which will be implanted subcutaneously to record adequate QRS complexes and P waves. The patients will be followed in outpatient clinic visits at 1, 12, 24 and 36 months after TAVR, or if symptoms suggestive of cardiac origin or relevant arrhythmic events occur. The device will be manually interrogated in each visit. Phone contacts will be also carried out every three months.
Cardiovascular disease (CVD) is the leading cause of end-stage mortality in chronic kidney disease (CKD) patients. However, CVD and CKD are inextricably linked, as microalbuminuria is an independent risk factor for CVD. Herein, we investigated changes in cardiac function and its risk factors in CKD patients who had different urine albumin-to-creatinine ratios (UACRs) and estimated glomerular filtration rates (eGFRs). We prospectively enrolled 182 CKD patients, classified into three groups based on UACRs and eGFRs. Fifty healthy volunteers were included as controls. Changes in clinical and echocardiographic parameters were assessed in each group, and factors independently associated with strain parameters were further analyzed. Compared with those in the control group, the albuminuria but unimpaired renal function (ALB-CKD G1-2), albuminuria and impaired renal function (ALB-CKD G3), and normoalbuminuric CKD (NACKD) groups had decreased left ventricular (LV), right ventricular (RV), and left atrial (LA) strains, the LA contractile strain being the only statistically comparable parameter. Stepwise multiple linear regression analysis revealed varying factors independently correlating with the LV global longitudinal strain. The LA reservoir and conduit strains independently correlated with LV diastolic function in stage 3 CKD associated with comorbid albuminuria or normoalbuminuria. LV function was a partial determinant of LA and RV function in the ALB-CKD G3 group, whereas ventricular and atrial function were independent of each other in the ALB-CKD G1-2 and NACKD groups. Clinical intervention should focus on specific factors affecting cardiac function in patients to reduce the risk of CVD-related death.
A wax-resin composite is made by melting thermoplastic hydrocarbon resin, optionally with an antioxidant. The melted thermoplastic hydrocarbon resin and waxes are blended at a temperature sufficient to melt the waxes. After blending and melting, the blended thermoplastic hydrocarbon resin and waxes are allowed to solidify. Solidification is followed by post-processing the wax-resin composite mixture to form slabs, pastilles, flakes or other forms. A method for producing a wax-resin composite comprises at least partially solvating a thermoplastic resin in a solvent to form a resin-solvent blend. This may be done at a heat of 80-85° C. A composition of molten wax is blended with the resin-solvent blend. The resin-solvent blend and a molten wax are blended to form a wax-resin blend. This is followed by removing the solvent from said wax-resin blend.
OBJECTIVE: The purpose of this study was to determine the effects of dietary supplementation of arginine (ARG) or guanidinoacetic acid (GAA), with or without phenylalanine (PHE), on the ascites susceptibility in the cold-stressed broilers fed canola meal (CM)-based diet.
METHOD: A total of 450 one-day-old male broiler chicks were randomly allocated to 30 floor pens with 6 replications for each of the 5 treatments. The dietary treatments were as follows: CM-based diet (control), CM-based diet + 2.57 g/kg ARG, CM-based diet + 1.8 g/kg GAA, CM-based diet + 2.57 g/kg ARG + 1.5 g/kg PHE and CM-based diet + 1.8 g/kg GAA + 1.5 g/kg PHE. The groups experienced cold stress induction starting at 32°C on day one, with gradual reductions to 15°C on days 21. The temperature was then held at 15°C for the remainder of the experiment.
RESULTS: The supplements ARG + PHE and GAA + PHE resulted in improved feed conversion ratios (FCR) when compared to the control group. In comparison with the control group, supplementation of ARG and ARG + PHE decreased the ascites mortality by increasing the plasma nitric oxide level (NO), blood O2 partial pressure, blood O2 saturation (SO2), and decreasing the blood CO2 partial pressure (PCO2) and right ventricle to total ventricle (RV:TV) ratio. Supplementation of GAA and GAA + PHE also declined ascites mortality by reducing blood PCO2 while increasing blood SO2 and plasma NO levels. Although plasma corticosterone level and RV:TV ratio were similar between the GAA and control groups, adding GAA + PHE significantly reduced both compared to the control group.
CONCLUSION: In summary, supplementing cold-stressed broiler chicken diets with 2.57 g/kg ARG may alleviate hypertension. Additionally, 1.8 g/kg GAA proves to be an effective substitute for dietary ARG in low-ARG diets, alleviating adverse effects from cold stress. Proper PHE formulation, at 1.5 g/kg in this study, is crucial when using ARG and GAA supplements.
FIELD: organic chemistry, experimental medicine, biology. SUBSTANCE: invention proposes a new agent for control of pathogens of bacterial, fungal and protozoan nature and for protection of live organism from radiation damage. Invention proposes derivatives of arylnitroalkens of the general formula:   where R 1  is H, CH 3 ,; R 2 ,R 3  are similar or different substituents taken among H, OCH 3 , OH, NO 2 , (CH 3 ) 2 N order. Use of agent decreases lethality of irradiated experimental animals and can be used in medicine, veterinary science and agriculture. EFFECT: broadened arsenal of agents showing effectiveness with respect to broad pattern of pathogenic microbes, fungi and protozoans. 2 cl, 5 tbl
In a solvent extraction process for preparing microspheres of a biodegradable polymer, the improvement comprising: preparing a homogenized antigen-sucrose matrix and adding a solvent to the sucrose-antigen matrix to form a solution; preparing a solution of a biodegradable polymer by adding a solvent to the polymer; adding the biodegradable polymer solution to the antigen-sucrose solution; adding an oil to the polymer-sucrose-antigen solution to form an emulsion having a controlled viscosity that corresponds to a predetermined average particle size of distributions of microspheres of biodegradable polymers; centrifuging the emulsion of controlled viscosity and removing the supernatant to obtain microspheres of a predetermined range of particle size distributions of from about 0.5 to about 7.0 micrometers. 
     In immunostimulating composition comprising an encapsulating-microsphere of the biodegradable polymer has an average particle size distribution such that the majority of the microspheres will be taken up by the villous epithelium section of the intestines of a mammalian subject when administered as a vaccine against diseases caused by entero-pathogenic organisms.A solvent extraction process for preparing microspheres of a biodegradable polymer. The process includes preparing a homogenized antigen- sucrose matrix and adding a solvent to the sucrose - antigen matrix to form a solution. Preparing a solution of a biodegradable polymer by adding a solvent to the polymer. Adding the biodegradable polymer solution to the antigen - sucrose solution. Adding an oil to the polymer - sucrose - antigen solution to form an emulsion having a controlled viscosity that corresponds to a predetermined average particle size of distributions of microspheres of biodegradable polymers. Centrifuging the emulsion of controlled viscosity and removing the supernatant to obtain microspheres of a predetermined range of particle size distributions of from about 0.5 to about 70 micrometers.
In appropriately selected patients an orthotopic neobladder (ONB) permits the elimination of an external stoma and preservation of body image without compromising cancer control after radical cystectomy. Voiding dysfunction (VD) following ONB can be divided into failure to empty bladder or failure to store urine. Failure to empty bladder by angulation of urethra is the most common cause. Failure to store urine can occur during daytime, night-time or both. VD that persists beyond 6 to 12 months warrants urodynamics evaluation to determine the cause and suggest plane of therapy. Voiding dysfunction has a detrimental impact on quality of life.

Among the various bowel segments studied, the ileum is ideal for ONB creation. A spherical reservoir, reconfigured from a de-tubularized ileal segment, offers the most desirable attributes like, adequate capacity, low intraluminal pressure, and good compliance. The patient of ONB reported 4-25% rate of clean intermittent self-catheterisation (CISC) for incomplete emptying. Daytime incontinence was present in 13% of patients. The rate of nocturnal incontinence is usually higher in the range of 15-40% in recent metanalysis. The success of ONB rely on detubularization of intestinal segment, sufficient capacity and proper configuration and position in the pelvis. Adequate capacity is achieved by using sufficient length, folding, and creation an ellipsoid or spherical configuration. The ONB should hold approximately 500 cc of urine at low pressure (at \< 15 cm H2O), empty completely (\< 100 cc urine), four to five times daily and allow the patient to sleep without awakening, while maintain normal body image

loss of the vesico-urethral reflex 'guarding reflex' in which increased urethral sphincter tone parallel to bladder distension, decreased patient vigilance during sleep resulting in reduced muscle tone and urethral closing pressure, decreased sensitivity of the membranous urethra after radical cystectomy, involuntary high-amplitude contractions of the reservoir secondary to bowel peristalsis and shifting of free water from the reservoir wall into the hyperosmolar urine are the main factor causing global and nocturnal polyuria in patient with ONB. Final, there is also evidence suggesting an increase in bowel activity during sleep. Maximum urethral closing pressure (MUCP) is the primary component responsible for daytime continence in patients with an ONB. However, Koraitim et al. suggest that nocturnal incontinence depends on three reservoir parameters: maximal contraction amplitude, baseline reservoir pressure at mid capacity, and MUCP.

Mebeverine is a derivative of reserpine, which has relatively specific effects on smooth muscle cells without atropine-like side effects in humans. It directly blocks voltage-operated sodium channels and inhibits intracellular calcium accumulation. It is three times more potent than papaverine in inhibiting the peristaltic reflex of the ileum.
Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment (Table 1). Guidelines to the active, progressive and early mobilization.
PURPOSE: A composition containing phosphatidylcholine for attenuating toxicity of an anticancer agent and an anticancer aid are provided to prevent or minimize side effects. CONSTITUTION: A composition for attenuating toxicity of an anticancer agent contains phosphatidylcholine as an active ingredient. The anticancer agent is cisplatin or paclitaxel. The toxicity is neurotoxicity, nephrotoxicity, or hematotoxicity. Phosphatidylcholine is isolated from eggs or soybeans. An anticancer aid contains phosphatidylcholine as an active ingredient.
Three decks of cards - diversified by frequency of use - depicting nouns, were presented in sets of 4 cards each. In an exchange modality, the task consisted in understanding the noun chosen by the patient and, in turn, by the rehabilitator. Any communicative modality (oral, gestural, verbal, graphic) was allowed. Word difficulty was graded based on the frequency of use and semantic proximity or distance between target and distractors.
In one embodiment, the invention provides a method of inducing differentiation of an epithelial cell. In another embodiment, the invention provides a method for inducing formation of a barrier within epithelium. In another embodiment, the invention provides a method for producing differentiated epidermis. In another embodiment, the invention provides a method of assaying for genetic propensity of a patient to develop a disorder associated with epithelial barrier formation. In anther embodiment, the invention provides a diagnostic test to determine the expression levels of Notch ligands, receptors, or other Notch signaling compounds in cells. In another embodiment, the invention provides novel Notch ligands. In another embodiment, the invention provides a method of preventing or retarding the progression of a benign or malignant disorder in skin.
A method for the complex treatment of the patients with the syndrome of diabetic foot at the stage of pyo-necrotic alterations provides for the regional indirect lymphotropic therapy using Lidase solution (16-32 U), Amicacin or Ceftriaxone at the single dose, Actovegin (5.0) and nicotinic acid (2.0). The drugs are administered to the fat of the middle fascial bed. Within 5-10 days until the arrest of the purulent excudation, the affected segment of the limb is treated with the ozone in the plastic bag at a concentration of 15 mg/L for 15 min providing for ozone environment in the wound with the pressure of 2- Hg. At the same time, ozone-oxygen mixture is administered subcutaneously around the edge of the wound defect, the volume of 40-60 cm, ozone concentration of 2000 μg /L, at a distance of 1- from the edge of hyperemic area, daily for 7-10 days. Every day upon ozonotherapy, the gauze wad with dimexid is applied to the pyo-necrotic wound surface. The wound is also treated with Rifampycin and Chemotrypsin.
The objective of this trial was to determine whether IGF-1 (MyotrophinTM) slows progression of weakness in amyotrophic lateral sclerosis (ALS). Three hundred thirty patients with ALS from 20 medical centers participated in this double blind, placebo-controlled two-year study. Half the patients received IGF-1 and the other half received placebo. The drug will be administered twice a day.

ALS is a neurodegenerative disorder that causes progressive muscle weakness and loss of motor neurons. IGF-1 is a neurotrophic factor essential for normal development of the nervous system and shows protection of motor neurons in animal models and cell culture systems. It is thought to block cell death pathways and promote muscle re-innervation and axonal growth and regeneration.
FIELD: medicine. ^ SUBSTANCE: invention concerns medicine and veterinary science, more exactly velvet antlers technology for making pharmacological and cosmetic preparations. There is offered the method which involves enzymatic hydrolysis of velvet antlers of drainage rate not exceeding 100 mcm with water and animal's pancreatic homogenate added at 100 g of pancreas per 1 kg of antler flour that is followed with water hydrolysate extraction by centrifugation and filtration, herewith enzymatic hydrolysis is performed with deer antler pancreas added in the weight ratio of antler flour: water 1:1.5, within 3-4 hours at temperature no more than 50C, hydrolysate extraction is carried out in the weight ratio of hydrolysate: water 1:1.5, within 3 hours. Centrifugation and filtration is followed with drying the extract containing an end product at temperature 50C and lower and pressure 0.9 atm. ^ EFFECT: invention provides preparing concentrate of deer antlers exhibiting high biological activity ensured by maximum content of hormones, growth factors, amino acids of macro- and microelements and vitamins. ^ 1 ex, 4 tbl
Patients treated with metformin and/or insulin or patients who do not tolerate metformin or treatment-naïve patients or patients who are not on active treatment took 1 film-coated tablet of 10 milligram (mg) Empagliflozin once daily until Week 14. Non responder patients were re-randomised at Week 14 to receive 25 mg empagliflozin, taken once daily, until end of treatment.
The invention provides a preparation method of carrier-free [*I]MIBG suitable for clinical application. The preparation method comprises the following steps: dissolving tin tributylbenzylguanidine in an alcoholic solvent, then adding the solvent into a phosphoric acid buffer solution, carrying out freeze-drying so as to obtain freeze-dried powder, adding the freeze-dried powder into a water solution containing *I ions, and then adding the water solution into an acidic buffer solution containing an oxidant to carry out reactions. Because the freezed-dried tin tributylbenzylguanidine powder cannot be dissolved in water, the unreacted tin tributylbenzylguanidine in the reaction liquid can be easily removed. The yield of [*I]MIBG is high. The labeling rate is high. The unreacted tin precursors and tin by-products can be easily and completely removed. The obtained [*I]MIBG does not contain any impurity. So the obtained carrier-free [*I]MIBG can be directly injected into human body, and is more suitable for clinical application.
The present invention relates to the production and characterization of monoclinic and polyclonic antibodies against human GR. More precisely, there have been produced and evaluated: a) a monoclinic antibody (2F8) and b) four polyclonic antibodies (10-26, BH, HH and EP) against GR. Furthermore, the present invention relates to the production and characterization of monoclinic and polyclonic antibodies against ER, ER and ER2. More precisely, there have been produced and evaluated: a) two monoclonic antibodies (mAN1 and mAN2) and two polyclonic antibodies (pAN1 and pAN2) against ER, b) two monoclinic antibodies (mBN1 and MB1C1) and two polyclonic antibodies (pBN1 and pB1C1) against ER1 and c) one polyclonic antibody (pB2) special for ER2. The mBN1 and pBN1 recognise -except for ER1- the ER2 too. Finally, the invention relates to the valorization of said antibodies in a series of techniques allowing the measurement of the quantity of the receptors (immuno-printing, immunocell chemistry, immunoprecipitation, Enzyme-Linked ImmunoSorbent assay (ELISA), immunohistochemistry) as well as the development of sandwich-ELISA methods capable of offering liable measurement of the receptors on the hyaloplasm of the cancer cells.
PURPOSE:To provide a physiologically active substance which is obtained from an edible mushroom, high in safety and has an effect on hypertension (vasodepressor). CONSTITUTION:This physiologically active substance contains a fruit body or a mycelium of Pleurotus sajor-caju (Fr.) Sing. as a component and has a vasodepressor activity. The physiologically active substance consists of an angiotensin conversion inhibitor contained in a fruit body and a mycelium of Pleurotus sajor-caju (Fr.) Sing. and soluble in a water-soluble solvent.
This group will be provided access to a website that will provide the following major links: a) Caregiving Resources (links to National Family Caregiver Association," etc.), b)Resources for DCGs (links to the Caregiving from a Distance," etc.), c) Cancer Information (links to National Cancer Institute, etc.). DCGs will be told that the study team will track usage of the website in order to assess which areas of the website are used most frequently. Any questions or concerns regarding use of the website can be sent online to the study's technical site, and the support staff will respond within 24 hours. As is current practice, DCGs can call an oncology nurse or oncologist to ask specific questions. Web-Only will deliver the lowest dose of the intervention.